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Abstract
Influenza is a virus that affects people of all ages; and thus, recommendations indicate
starting vaccinations: at the age of six months. However, within the population there lies a group
of vulnerable people that includes elderly adults. Elderly adults are a population at high risk for
poor outcomes related to influenza as they are frailer and have a lower immune response to the
influenza vaccination. This paper includes a case report of is on a 56 year old Caucasian man
who presented to the clinic with symptoms that were found to be related to influenza. The rapid
influenza swab revealed positive influenza and the client was noted to be on methotrexate for his
arthritis, which can compromise one’s immune system. He was noted to be updated on his
influenza vaccination, but over the recommended two days of illness onset to when treatment
with anti-viral should be administered. Influenza vaccinations remain an important and effective
health measure in helping reduce poor outcomes such as hospitalizations and mortality in elderly
adults. Recent research about the effectiveness of influenza vaccinations has been put into
question. Frailty and vaccine effectiveness in the elderly were found to have a correlation. This is
an important finding as addressing frailty in the elderly has led to the research of using high-dose
vaccination to help improve immune responses. Clinicians should take into account frailty and
the possibility of using high-dose vaccinations in the elderly to improve their outcomes.
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Influenza Vaccine Effectiveness in the Elderly
Background
Influenza is a communicable illness that can be fatal and lead to significant
hospitalizations in vulnerable groups, such as the elderly, pregnant women, and clients with
chronic conditions (Lee, Chen, Tang, & Lan, 2014). Most every winter an influenza epidemic
occurs, causing about 5 to 20 percent of people to become ill (Lee, Chen, Tang, & Lan, 2014).
Illnesses due to influenza lead to approximately 300,000 hospitalizations and 36,000 deaths
annually (Lee, Chen, Tang, & Lan, 2014). However, during a pandemic season around 90
percent of deaths occur in people 65 years or older (Lee, Chen, L., Tang, G., & Lan, T, 2014).
In order to avoid the influenza disease and its negative consequences, the main approach
for prevention of seasonal outbreaks is vaccinating, making influenza a vaccine-preventable
disease (Lee, Chen, Tang, & Lan, 2014). This mainstay approach to prevention is universally
recommended for the elderly population, however, evidence to support that vaccinations in the
elderly reduce influenza related mortality is insufficient (Simonsen et al., 2007). Many trials
indicate that vaccinations help to prevent influenza illness in the young and healthy elderly
population. However, no data from studies show benefits for those 70 years and older and this
age group accounts for most influenza- related deaths (Simonsen et al., 2007). The efficacy and
effectiveness of vaccination for influenza remains uncertain due to this sparse evidence derived
from healthy young adults. The evidence for vaccine effectiveness (VE) in frail elderly is even
less (Lee, Chen, Tang, & Lan, 2014).
According to Simonsen et al. (2007) effectiveness of the influenza vaccine in elderly
nursing home clients actually declines when combined with developing functional impairment.
This indicates that frailty could be associated with vaccine-induced antibody responses (Lee,
Chen, Tang, & Lan, 2014). It was found that the VE within the elderly especially those 65 years
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and older had a large VE gap when confirmed against laboratory influenza results. This range
was between 33 to 86 percent and this inconsistency has led to discussion about whether the
influenza vaccine benefits elderly people against potential severe outcomes such as
hospitalizations or mortality (Lee, Chen, Tang, & Lan, 2014).
Case Report
MA is a 56 year old male who presented to the clinic in January of 2018 with complaints
of fever, chills, cough, joint pain and fatigue for past the five days. MA denied being around
anyone who was currently sick, and denied any travel out of the country. He stated he had no
nausea, vomiting, loss of appetite, or diarrhea. He reported generalized aches and pains. His
cough was mostly nonproductive. He denied any hemoptysis or discolored sputum. He had no
chest pain and no shortness of breath. He reported the use of ibuprofen 400mg every four to six
hours for generalized aches. He reported he did not check his temperature at home but felt the
chilled.
Upon evaluation, MA’s medical history included rheumatoid arthritis and hypertension.
He had no past surgical history and no known allergies. Medications included lisinopril, Humira,
Methotrexate injections, and a multivitamin. His social history included no tobacco use and he
reported drinking a glass of wine once or twice a week. He was also up to date on his influenza
vaccine. Upon physical examination, vital signs included blood pressure 142/92, heart rate 90,
respirations 30, and temperature 102.4 degrees Fahrenheit. In general the patient looked unwell,
but in no acute distress. Head, ear, eyes, nose and throat exam (HEENT) revealed his head to be
atraumatic and normocephalic. Pupils were equal, round, and reactive to light. Extraocular
movements were intact. There was no icterus, cyanosis, or pallor of the conjunctivae. His
bilateral ear exam including the pinna, tragus, and external canal non-tender. His ear canal and
tympanic membranes were translucent and mobile. Nose inspection revealed pink nasal mucosa,
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septum midline and patent nares bilaterally. Throat inspection presented an oropharynx with no
erythema or exudate. Along with moist mucous membranes, no thrush, no lesions, and good
dentition were noted. The neck was supple and trachea was midline. No cervical
lymphadenopathy present upon examination. The chest examination revealed adequate air
exchange bilaterally, no crackles, wheezes or rhonchi were appreciated. Heart sounds one, and
two heard, and no murmurs or gallops present with regular rate and rhythm. No murmurs,
gallops, or rubs were noted.
A diagnostic workup included a complete blood count with differential and
nasopharyngeal influenza swab. Pertinent laboratory results included a positive rapid influenza
antigen test and white blood cell count (WBC) was 9.7. MA was informed that he was positive
for influenza; however, he was past the recommended two days of illness onset when treatment
with an anti-viral should be administered. He was offered prescription cough syrup with codeine
5mL by mouth three times a day for seven days if needed, given a dose of Tylenol 650mg prior
to leaving the clinic, and rechecked temperature upon discharge. The patient was instructed to
take Tylenol as needed for aches and pain, to drink many liquids, and stay home and rest. Also
the patient was informed to not exceed recommended daily dosage of Tylenol. If he did not get
any better, the client was informed to come back to the clinic for further evaluation such as chest
x-ray and more lab work. Education on vaccinations was provided because MA is entering the
spectrum of old age and has multiple comorbidities, thus it is imperative that he stays up to date
on his yearly influenza vaccine. Older adults with multiple chronic medical conditions are at
more risk for serious illness and even death.
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Literature Review
The body of evidence found for this literature search was broad. Literature found was
based on different aspects of evidence including previous studies done on vaccine effectiveness
of the elderly, assessment of frailty, and the comparison of vaccine effectiveness for influenza.
The interventions and outcomes that were used to measure this search were diverse.
Furthermore, none of these studies assessed a placebo-controlled study or randomized control
trials, as this would be unethical.
A search strategy was conducted using the University of North Dakota’s Harley French
medical library. Three different search engines were used in an attempt to search for information
and included CINAHL, PubMED, and Clinical Key. The Keywords used were associated with
the interventions and included that of influenza vaccine, elderly and/or aged, effectiveness and
mortality.
The literature search on the topic of vaccine effectiveness in reducing mortality in the
elderly compared to elderly who did not receive the vaccine lead to a wide range of results.
Consequently, the articles reviewed had a variety of interventions and means of research. This
led to the inclusion of comparing different variations in influenza vaccines, and if one vaccine
maybe more beneficial than the other. The consensus was that VE does diminish with increased
ageing and that frailty has an astounding effect on VE. Moreover, vaccination still remains an
important intervention for influenza, as it is associated with a reduction in hospitalizations and
adverse outcomes for the elderly.
An important aspect to account for in the ageing process is frailty. Frailty is considered a
measure of health, function, and vulnerability and can predict health outcomes often better than
age alone (Andrew et al., 2017; Simonsen et al., 2007). Therefore, frailty is an important

INFLUENZA VACCINE EFFECTIVENESS IN THE ELDERLY

8

contender that should be addressed when measuring VE. However, in most proposed studies on
the influenza vaccine, it is inadequately regarded. (Andrew et al., 2017). Frailty can often be
difficult to assess in patient charts as it is calculated by addressing an accumulation of deficits in
health using the frailty index (FI). Deficits in health can be signs and symptoms of diseases,
disability, and laboratory, electrocardiographic, or radiographic abnormalities. As a patient
accumulates more of these deficits, they are more likely to be considered frail. The FI generally
is disclosed as a ratio of deficits present compared to the number of deficits considered (Searle,
Mitnitski, Gahbauer, Gill, & Rockwood, 2008).
Andrew et al. (2017) performed a case-control study to assess VE in the elderly adult
with a focus on frailty. The authors concluded that VE does display differences among non-frail
elderly adults and frail older adults in that VE was very good (77.6%) among nonfrail elderly,
lower in prefrail elderly, and was all most nonexistent in most frail elderly. This study indicated
that frailty assessment is important as it addresses function status in the over-all health status of
patients.
Mannino et al.( 2012) included an observational study that compared the vaccines MF59
adjuvant trivalent inactivated vaccine (ATIV), versus the nonadjuvanted trivalent inactive
vaccine (TIV) in elderly 65 years and older. ATIV was used as a comparison to the standard
vacation because it was established for the elderly population to help increase their immune
responses to the influenza vaccination. In this study, it was found that the elderly who received
ATIV had more baseline hospitalization due to frailty; however, the study still found that those
who obtained ATIV had a twenty-five percent risk reduction of hospitalization during peak
influenza season than elderly who received TIV.
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Similarly, a study done by Domnich, Arata, Amicizia, Puig-Barbera & Gasparini (2017)
executed a systematic review of observational studies to find out if using an adjuvant (MF59TIV) would help to increase vaccine potency; thus allowing, a more rapid and broader immune
response in the elderly. These particular authors assessed the adjuvant MF59 which has
demonstrated immuno-stimulatory proprietaries such as activating local immune cells at the
injection site and promoting transition of monocytes to dendritic cells. This analysis of adjuvants
holds value for the elderly as people begin to age; it can consequently cause a reduction in innate
and adaptive humoral and T-cell mediated immunity (Andrew et al., 2017). This is a normal
process of age-related decline and reduces one’s ability to fight off the influenza infection. This
process of ageing is known as immunosenescence (Andrew et al., 2017). The authors of this
article assessed observational studies, which are great resources to look at vaccine effectiveness
in the field, and found that VE with MF59-TIV reduced hospitalizations for pneumonia/influenza
by more than 50 percent and is an effective vaccine at reducing influenza related outcomes in the
elderly.
In another article by DiazGranados et al. (2014) a high dose vaccine (IIV3-HD)
compared to the standard-dose vaccine (IIV3-SD) enhanced antibody responses against
influenza in people 65 years or older. They found similar results in that a higher dose vaccine did
in fact provide enhanced protection against confirmed influenza illness.
The theory of high dose vaccination holds value in another study by Nace et al. (2015)
who found that in the frail elderly, high dose vaccination produced higher-level responses for
almost every strain of influenza. In this literature search, this was the only study found that
performed a randomized control trial (RCT) within long-term care facilities on clients 65 years
or older. The study compared standard dose influenza vaccines versus high dose vaccinations. In
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order to compare the two vaccines blood samples were obtained and analyses of geometric mean
titers (GMT) were used as the outcome. Using this means, the study found that in frail older
adults the GMT’s were higher with the high dose vaccination indicating an enhanced immune
response.
In an additional study by Wilkinson et al. (2017), a systematic review was conducted to
determine whether higher-dose vaccines of influenza were more effective and usage was safe in
the elderly aged 65 years or older. Their theory was that elderly are more pressured to receive the
influenza vaccine to help reduce poor outcomes; however, they are prone to having lower
antibody reaction to vaccines rendering them less effective. Thus, raising the dose of influenza
antigens may increase their immune response and enable the vaccine to be more effective. The
outcome addressed in this study did not look at reduction in mortality, but rather a reduction in
laboratory-confirmed illness. When addressing this outcome, it was found that the elderly whom
received a high-dose influenza vaccine had a 24 percent reduction in the risk of laboratoryconfirmed influenza compared to those who received the standard-dose vaccine. The evidence
that high-dose vaccinations are effective at reducing the amount of influenza cases is paramount
as a study by Jefferson et al. (2005), whom performed a search of electronic databases, found
that VE of trivalent influenza vaccines had a minimal effect on the reduction of cases within the
elderly population. Nevertheless, the standard dose of the influenza vaccination proved to have a
better impact on complications of influenza such as hospitalizations and all-cause mortality
rather than cases of influenza.
Thomas (2014) who also performed a systematic review found the outcome of mortality
often was an all-cause mortality, which is a non-specific outcome and can be subject to unknown
biases. He concluded that specific outcomes would be more applicable if they included

INFLUENZA VACCINE EFFECTIVENESS IN THE ELDERLY

11

laboratory-proven influenza or pneumonia deaths. Moreover, the author found that influenza
associated death for those greater than 80 years of age was 11 times higher than the elderly ages
65-69 and that these numbers continued to remain true even with increasing vaccination rates
and vaccine match. In this randomized control study, the author found evidence that vaccine
efficacy does in fact decrease with increasing age.
Campitelli, Rosealla, Stukel & Kwong (2011) conducted a cohort study to estimate the
effectiveness of influenza vaccines in the elderly and whether it helps to reduce all-cause
mortality. These authors wrapped up this literature search with the convincing evidence that
elderly who receive an influenza vaccine are 39 percent less likely to die from any cause during
influenza season when compared to non-vaccinated elderly. In addition to this evidence, they
discovered that vaccinated individuals were also 45 percent less likely to die during preinfluenza season and 26 percent less likely to die during post-influenza season. This indicates
that not only does the influenza vaccine help reduce mortality, but it also has the presence of
residual confounding effects during times when the influenza virus is not circulating.
Throughout this search, there was one article which found that biases do exist within
research studies and do affect outcomes within the elderly. An article by Wong, Campitelli,
Stukel, & Kwong (2012) whom performed a cohort study over nine influenza seasons used
instrumental variable (IV) analysis. IV analysis is a method of analysis that has been found to
remove hidden bias in observational studies. This study using logistic regression found that
adults 65 years and older who received an influenza vaccination demonstrated a reduction in
both hospitalizations and mortality (33%) during influenza season and significant reduction in
mortality after influenza season. However, when using IV analysis, which adjusted the
association of influenza vaccination mortality during the influenza season, analysis expressed no
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significance between the two seasons. These results also held true of IV analysis of postinfluenza vaccination.
Through this research it confirmed that with age comes a decrease in vaccine
effectiveness ranging from 17 to 60 percent, and that biases do exist within the research of VE in
the elderly (Nace et al., 2015). Influenza combined with pneumonia ranks as the eighth leading
cause of death and is the number one vaccine preventable death in the United States. A goal of
Healthy People 2010 is to have residents in long term care facilities reach an immunization goal
of 90 percent for both influenza and pneumonia (Nace et al., 2015). This is imperative for the
elderly and especially those in long-term care facilities as they are more exposed to the influenza
virus, have reduced immune responses, and increased mortality rates compared to other
populations (Nace et al., 2015). An important indicator to help assess if one is in need of a
vaccination, especially a high-dose vaccination, is frailty and most often this incompletely
captured in the health record. Frailty is an important confounder to address when assessing VE in
the elderly as a lack of assessment can lead to underestimating VE in this specific population
(Nace et al., 2015). In addition, if frailty assessment is overlooked for this population it can be
considered frailty bias. The value of the influenza vaccination remains high as vaccinations for
this particular age have been shown to reduce poor outcomes and proven to be the most cost
effective health measure in reduction of the influenza virus.
Learning Points
•

The best way to accomplish the Healthy People goal, as proven by presented research is
with the use of high-dose vaccines to help produce a stronger immune response in the
elderly.
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Assessment of frailty is important as the impact of influenza VE varies from very good in
a healthy adult to almost nonexistent in the frail elderly (Nace et al., 2015).

•

Interventions for providers to help improve rates of vaccination include the use of
reminders for patients; such as, reminder postcards or a phone call. To help increase
access to influenza vaccinations providers and clinics could promote group visits or make
home visits.

•

A second option could be to place facilitators in clinics alongside health professionals to
help with education about influenza and influenza vaccinations to the patients and their
caregivers (Thomas, Russel & Lorenzetti, 2010)..
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